References[1]Craig T, Magerl M, Levy DS, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient Hereditary Angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. This evidence concerns the gene C1S and hereditary angioedema.